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Abstract
The purpose of this study was to evaluate the effects of
hepatic vein occlusion by stent-graft used in transjugular
intrahepatic portosystemic shunt (TIPS). The experiments
were performed in six healthy pigs under general anesthesia.
Following percutaneous transhepatic implantation of a port-
a-cath in the right hepatic vein, TIPS was created with a
stent-graft (Viatorr; W L Gore, Flagstaff, AZ, USA). The
outflow from the hepatic vein, blocked by the stent-graft
was documented by injection of contrast medium and re-
peated injections of 99Tcm-labeled human serum albumin
through the port-a-cath. After 2 weeks, the outflow was re-
evaluated, the pigs were sacrificed, and histopathologic
examination of the liver was performed. Occlusion of the
hepatic vein by a stent-graft had a short and temporary ef-
fect on the outflow. Histopathological examination from the
affected liver segment showed no divergent pattern. Stent-
grafts used in TIPS block the outflow from the liver vein,
but do not have a prolonged circulatory effect and do not
affect the liver parenchyma.
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Over the last 10 years, transjugular intrahepatic portosys-
tematic shunt (TIPS) procedures have almost completely
replaced surgical portosystemic shunts in treatment of pa-
tients with portal hypertension and repeated bleeding from
gastroesophageal varices [1–5] or refractory ascites. Long-
term results of TIPS are, however, unsatisfactory due to the
development of pseudointimal hyperplasia in the shunt
channel and/or intimal hyperplasia in the adjacent hepatic
vein [6].
To overcome these problems, stent-grafts have been used
[7–12]. These stent-grafts separate the shunt channel from
the liver tissue, bile ducts, and the wall of the hepatic vein,
preventing development of hyperplasia.
Following TIPS, blood from the portal vein passes
through the created shunt toward the right atrium, whereas
flow to the intrahepatic portal vein branches is substantially
decreased [13]. The cranial portion used for the TIPS stent-
graft might block the outflow from the hepatic vein to which
the shunt extends. A decrease in the hepatic arterial flow to
the liver segment drained by the blocked liver vein was
reported [14] as well as segmental liver ischemia [15]. Pa-
tients treated with a TIPS often have an impaired liver
function. Reduced blood flow through one liver segment can
cause further deterioration.
The present study was performed in order to evaluate if
the outflow from the hepatic vein blocked by a stent-graft,
causing a ‘‘pseudo-Budd–Chiari-syndrome,’’ changed over
2 weeks of time and if there were any possible consequences
for the affected liver segment.
Materials and Methods
Animals and Anesthesia
Six healthy pigs, 36–40 kg body weight, were used for the
experiments after approval from the local ethics committee for
animal research. All procedures were performed under general
anesthesia, induced by intramuscular injection of 2 mg/kg azap-Correspondence to: Inger Keussen; email: inger.keussen@skane.se
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erone (Stresnil Vet; Leo, Helsingborg, Sweden), followed by
intravenous injection of 2–4 mL thiopental (Pentothal Natrium;
Abbott Lab, N. Chicago, IL, USA) 5% solution. Following intu-
bation, anesthesia was maintained by artificial ventilation with a
mixture of oxygen and nitric oxide and continuous infusion of
ketamin-hydrocloride (Ketalar; Parke-Davis, Solna, Sweden),
1 mg/min, and midazolam (Dormicum; Roche, Stockholm, Swe-
den), 5 mg/h. At the end of the experiments, all animals were
sacrificed by an intracardial injection of an overdose of potassium.
Preparation of Radiopharmaceuticals
Human serum albumin (HSA) labeled to 99Tcm is frequently used
for circulation and blood flow studies. In our study, we used
TechneScan HSA (Mallinckrodt Medical B.V., Petten, Holland),
which was labeled to 99Tcm according to the manufacturers
instructions. Freeze-dried HSA was dissolved in 8–10 mL per-
technetate solution (406–1790 MBq). After a 15-min incubation
time, the preparation was ready to use. All preparations were
tested within 5 h after labeling with instant thin-layer chroma-
tography (ITLC-SG; Gelman Sciences, Ann Arbor, MI, USA),
using 1 · 8-cm strips and 2-butanone (ethyl-methyl-ketone) as the
mobile phase. The amount of free pertechnetate varied between
0.04% and 0.45% (mean: 0.25%). The injected activity was
determined by measurements of the syringe before and after
injection in a radioisotope calibrator (CRC-35R; Capintec,
Pittsburgh, PA, USA). Blood samples were weighed and measured
for radioactivity in a gamma counter (1282 CompuGamma CS;
Wallac Oy, Turku, Finland). Assuming that the blood volume in
pigs was 8% of the body weight, the percentage of the injected
radioactivity leakage to peripheral blood was calculated.
Procedures
The left jugular vein was punctured after surgical cut down and
thereafter catheterised. The tip of a 5 F Cobra catheter (Cordis,
Johnson & Johnson CO, Roden, Netherlands) was manipulated
jointly with a 0.035 glidewire (Terumo, Tokyo, Japan) into a
peripheral branch of the right hepatic vein. Subsequently the tip of
the catheter was used as a target for the percutaneous transhepatic
puncture of this vein. The puncture was performed using Seldinger
technique, with a 20G needle (Mediplast, Malmoe, Sweden),
subsequently replaced over a 0.018-in. Cope wire by a 5F catheter
(transhepatic cholangiography catheter cannula, both from William
Cook Europe, Bjaeverskov, Denmark). Contrast injection (Omni-
paque, 350 mL I/mL; Amersham Health, Oslo, Norway) confirmed
free outflow from the right hepatic vein.
Thereafter, a subcutaneous reservoir (port-a-cath; Deltec,
Smiths Medical Industries, St. Paul, MN, USA) was implanted
subcutaneously at the level of the liver, with the tip of the catheter
placed in the right hepatic vein, approximately 5 mm from the
confluence into the inferior vena cava. A transjugular, transhepatic
access to the portal vein was created with a Cook TIPS Set
(William Cook Europe). Through the port-a-cath, the radionuclide
99Tcm-HSA was injected into the right hepatic vein. Samples of
venous blood from the peripheral circulation was obtained after 1,
3, 5 and 10 min, before the TIPS was created.
The TIPS was created with a 10 · 40-mm stent-graft,
(VIATORR; W L Gore, Flagstaff, AZ, USA). The stent-graft was
dilated with a 10 · 40-mm balloon (MediTech; Boston Scientific,
Watertown, MA, USA). Free flow through the TIPS channel was
confirmed by portography (Fig. 1A). Occlusion of the right hepatic
vein by the inserted stent-graft was documented by injection of
contrast medium in the port-a-cath (Fig. 1B). Injection of 99Tcm-
HSA through the port-a-cath in the occluded right hepatic vein was
followed by blood sampling from the peripheral vein after 1, 3, 5,
and 10 minutes.
A repeated injection of 99Tcm-HSA as described earlier was
planned for 2 weeks later. Unfortunately, all of the port-a-caths had
dislodged from the intended location in the right hepatic veins.
Under fluoroscopic guidance, percutaneous puncture of the right
Fig. 1. (A) Portography after TIPS shows blood flow
through the TIPS channel. (B) Percutaneous contrast injec-
tion show blockage of the right hepatic vein after TIPS.
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hepatic vein was performed with a 20G needle, toward the cephalic
portion of the stent-graft. The position of the needle in the oc-
cluded hepatic vein was confirmed by contrast injection. The
99Tcm-HSA was thereafter injected through the needle. The sam-
pling of peripheral blood was repeated in the same intervals as
previously.
Following sacrifice of the animals, parts of the liver, including
segments with the occluded hepatic vein, stent-graft, and normal
liver from the left lobe were resected and sent for histopathological
examination for evaluation of possible changes secondary to ve-
nous congestion. Three samples from each liver lobe were evalu-
ated. The liver tissue was fixed in 10% natural buffer formalin and
embedded in paraffin. Slides were prepared and stained with
hematoxylin and eosin according to standard protocols.
Results
Despite successful insertion of the stent-grafts in the in-
tended position, the hepatic vein was not completely
blocked in one pig due to an anatomic variation and this pig
was excluded from the study. In one pig, the placed stent-
graft was too short and its bare part did not reach far enough
into the portal vein. This portion of the shunt was therefore
supported with a 12 · 80-mm stent (Smart, Cordis) to obtain
optimal blood flow through the shunt channel. One pig died
of respiratory failure just prior to the final radionuclide
examination. Consequently, the experiments could only be
completed in four pigs, which excluded the possibility of
statistical evaluation at the end point of the study.
The radionuclide examination after TIPS showed pri-
marily (after 1 min) decreased outflow from the occluded
hepatic vein, compared to the measurements before TIPS.
However, after 3 min, the outflow was normalized (Fig. 2).
Values obtained in four pigs after 2 weeks were comparable
to the ones obtained before TIPS, indicating good outflow
from the liver vein closed by the stent-grafts. There were no
complications secondary to dislodgement of the subcuta-
neous reservoirs from the liver.
The stent-grafts were fully patent in one pig; the
remaining were occluded to 75–100%.
One animal showed macroscopic cirrhosis, whereas the
others showed no macroscopic fibrosis, cirrhosis, steatosis,
or sign of congestion. Most of the samples had a micro-
scopically similar pattern with normal acinar structure.
There were no marked portal fibrosis, no bile-duct damage,
and no interface hepatitis. A few neutrofils, lymphocytes,
and plasma cells were found in the portal tract. Terminal
hepatic venule and sinusoids showed minor dilatation but no
fibrosis around central veins.
One pig had a different histopathological finding. This
pig had signs of cirrhosis with marked infiltration of neu-
trophils, lymphocytes, and plasma cells in both samples,
findings most likely related to chronic defects. In two more
samples, from different pigs and from different lobes, light
portal fibrosis was found with a mild infiltration of neu-
trophils, lymphocytes, and plasma cells, but no fibrosis
around central veins.
Discussion
The advantage of stent-grafts in TIPS is its ability to sepa-
rate the shunt channel from the liver parenchyma, bile ducts,
and the wall of the hepatic vein, preventing development of
pseudointimal and intimal hyperplasia [2, 4, 11]. The stent-
graft has also been used to treat hemorrhage after extrahe-
patic portal vein puncture during a TIPS procedure [16].
Several graft materials have been used for construction of
stent-grafts [8–10]. The Viatorr stent-graft (W L Gore,
Flagstaff, AZ, USA) used in our study is a nitinol-polytet-
rafluoroethylene stent-graft for TIPS, commercially avail-
able and easy to handle [17]. These dedicated stent-grafts
can also be safely used in patients who need a TIPS while
waiting for liver transplantation [18].
Changes in the hepatic perfusion of the liver occur after
TIPS placement [13]. The blood flow to the intrahepatic
portal vein branches is diminished and the liver is supplied
with blood mainly from the hepatic artery. The cranial
portion of a stent-graft used for TIPS, positioned in a hepatic
vein, blocks the outflow from this vein [14, 15]. It has been
Fig. 2. Measurements of 99Tcm-HSA
in peripheral blood before and after
occlusion of the hepatic vein with a
stent-graft; mean values.
122 I. Keussen et al.: Liver Vein Occlusion
shown that the use of stent-grafts can decrease perfusion to
the adjacent liver segment, due to occlusion of a liver vein
[14]. This can potentially have serious consequences for a
patient with an already impaired liver function. In cirrhotic
patients, computed tomography has revealed segmental liver
ischemia in a few cases [15] remaining for a long time.
In our experiment, we wanted to evaluate venous outflow
from the liver segment, drained by hepatic vein, which be-
came occluded by the stent-graft used for TIPS. Activity of
99Tcm-HSA injected in the occluded liver vein measured in
peripheral blood was primarily slightly decreased. However,
in our experiments, the activity reached the same level after
3 min as that measured before TIPS. Our findings indicated
that occlusion of one liver vein affected the venous outflow
only for a very short period of time when the other liver
veins remained open. The measurements obtained after 2
weeks confirmed these findings.
Histopathological assessment showed normal acinar
structure in most of the samples. One pig had a divergent
pattern, probably due to more chronic changes. Two pigs
showed a very light increase of fibrosis, which might be
within normal anatomical variation.
Statistical evaluation of our material was not possible
because completion could only be performed in four ani-
mals due to the complications described earlier. Another
limitation of the study is, of course, that it was performed in
healthy animals and the findings can be different in patients
with cirrhosis.
We conclude in our limited experimental study that a
‘‘pseudo-Budd–Chiari syndrome,’’ which appeared after
insertion of a stent-graft in the TIPS channel, had no sig-
nificant impact on venous outflow. Occlusion does not
cause obvious changes in the affected liver segment.
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